Deep Research Global

Deep Research Global

Earnings Analysis - Lennar, Trip.com, Kestra Medical & More

LEN, KMTS, RLGT, PLAY, TCOM, FPS, VRA, and LUXE

Deep Research Global's avatar
Deep Research Global
Sep 22, 2026
∙ Paid

Welcome to Deep Research Global - The institutional-grade investment analysis newsletter, built exclusively for savvy investors.

The insights that move investment decision, before the crowd catches on. Become an “Annual” member now & get 51% off.

As a paid member you get access to:

  • Deep-dive fundamental analysis reports & investment insights

  • Earnings analysis of key releases

  • One subscription. Unlock full archive - 100s of stock/company analysis reports (updated regularly)


In case you missed it:

  • Blackstone (BX) - Fundamental Analysis Report

  • Thermo Fisher (TMO) - Fundamental Analysis Report

List of All Reports - Check It Out


Earnings analysis included today, at a glance:

  • Lennar Corporation (LEN) Q3 FY2026

  • Kestra Medical Technologies (KMTS) Q1 FY2027

  • Radiant Logistics (RLGT) Q4 FY2026

  • Dave & Buster’s (PLAY) Q2 FY2027

  • Trip.com (TCOM) Q2 FY2026

  • Forgent Power Solutions (FPS) Q4 FY2026

  • Vera Bradley (VRA) Q2 FY2027

  • LuxExperience (LUXE) Q4 FY2026


Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.


Lennar Corporation (LEN) Q3 FY2026

Lennar’s third quarter captured the push and pull of today’s housing market. The homebuilding giant earned $284 million, or $1.19 per diluted share, on total revenues of $8.0 billion, down from last year as rates squeezed affordability.

Key numbers from the quarter

LEN Q3 FY2026 snapshot:
- Total revenues: $8.0B
- Deliveries: 20,840 homes (-3% YoY)
- New orders: 20,879 homes (-9% YoY)
- Backlog: 16,857 homes worth $6.3B
- Gross margin on home sales: 15.8%
- Average sales price: $372,000 (with ~12% incentives)

Revenue of $8.05 billion missed consensus estimates of $8.33 billion, and the stock reaction reflected investor unease about order trends. A 9% drop in new orders is the metric bears will focus on.

The incentive load of roughly 12% of sales price shows what it takes to move homes at 6.8% mortgage rates. That incentive spending is what keeps gross margin at 15.8% rather than the 20% ± levels of stronger cycles.

Backlog of 16,857 homes worth $6.3 billion still provides a solid revenue runway into fiscal 2027. Even with softer orders, Lennar has months of visible deliveries already sold.

Volume over price, by design

Lennar’s strategy is deliberately volume-first: keep starts and sales paces steady (both ran at 4.1 homes per community per month across 1,713 active communities) to absorb fixed costs and turn land, even if margin suffers.

Management commentary leaned on a familiar but true structural point: the US housing shortage persists, so demand from primary buyers plus single-family-rental and build-to-rent investors provides a floor under volumes.

Guidance details for investors:

  • Q4 new orders of 19,500 to 20,500 homes; deliveries of 22,000 to 23,000.

  • Q4 gross margin of 15.5% to 16.0%; average sales price of $370,000 to $380,000.

  • Full-year 2026 delivery target moderated to about 80,000 to 81,000 homes from 82,000 to 83,000.

  • SG&A expected to improve toward 8.7% to 9.0%, showing cost discipline even in a down cycle.

The affordability math: at a 6.8% mortgage rate, incentives near 12% of price are effectively Lennar buying down the rate for the buyer. Volume survives, margin pays the bill.

Watch items

Management noted rates have moved even higher since quarter-end, and consumer confidence is slipping. Order momentum and incentive levels are the two numbers that will decide how the stock trades from here.

Inflation running above the Fed’s target, geopolitical tension and higher oil prices are all rate drivers.

None of those are within Lennar’s control, which is why the company manages the one thing it can: pace.

Bottom Line for Investors

LEN at a glance:

Why bulls are buying: Structural housing shortage, disciplined
volume strategy, $6.3B backlog, and SG&A leverage improving
toward 8.7-9.0%.

Best for: Investors who want large-cap, liquid exposure to US
housing with a shareholder-return track record.

Main risks: Mortgage rates staying near 7%, order declines
extending, margin compression from incentives.

Catalysts: Any rate relief, Q4 delivery execution, build-to-rent
demand absorbing supply.

Official sources & data:

  • Q3 2026 earnings release

  • Lennar investor relations

  • Q3 2026 press release PDF


Kestra Medical Technologies (KMTS) Q1 FY2027

Keep reading with a 7-day free trial

Subscribe to Deep Research Global to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2026 Deep Research Global · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture